Who would have thought that in the worst market for equipment in memory, they actually made money... even on lower sales. Paid off the debt and have cash... if not much. Selling at an EV to sales of less than 0.40 or 0.50 with the preferred.

The market is not going away either, steroid injection has little long term benefit vs laser:

"Diabetic macular edema is the leading cause of visual loss in diabetic retinopathy. Laser therapy has been the standard of care for patients with persistent or progressive disease. More recently, it has been suggested that IVTA injection may improve VA. It doesn't."

Blueline will doubtless register their shares after the summer and raise the share count 1.6 million (they paid 3.2 for them, so that's ok).